Food therapy: Coffee Reduced Risk of Melanoma, Particular in People with Altered GSTM1 and GSTT1 Gene

By Kyle J. Norton


In compared to herbal medicine, food therapy even takes longer to ease the symptoms, depending to stages of the treatment which directly address to the cause of disease.

Intake of coffee regularly may have positive effect in reduced risk of Melanoma, particular in healthy people with alternated genes GSTM1 and GSTT1 expression, a renowned institute study suggested.

Melanoma is a type of malignant skin cancer caused by DNA damage, most often caused by ultraviolet radiation from sunshine or tanning beds inducing irregular growth of skin cells.

Coffee, becoming a popular and social beverage all over the world, particular in the West, is a drink made from roast bean from the Coffea plant, native to tropical Africa and Madagascar.

According to the Istituto Dermopatico dell'Immacolata, in compared to low coffee intake, high frequency of coffee drinking (>once daily) with ≤7 times weekly , showed a significant lower risk of melanoma.

Interestingly, in the group people with GSTM1 and GSTT1 null polymorphisms(altered gene expression) subjects, coffees showed an extreme high protective effect against forming of Melanoma.

Also in the searching of PubMed and EMBASE databases from the earliest available online indexing year to March 2017 for a dose-response meta-analysis on prospective cohort studies, researchers at the Jagiellonian University Medical College, insisted that linear dose dependent are associated to the development of melanoma risk and total coffee consumption.

Risk of melanoma is reduced by 3% for every cup of coffee intake per day.

Dr. Micek A, the lead author in the joint study said, "(According to) a total of seven studies eligible for meta-analysis were identified that comprised 1,418,779 participants and 9211 melanoma cases,......coffee intake may be inversely associated with incidence of melanoma".

Further in the demonstration of 2 case-control studies (846 MM patients and 843 controls) and five cohort studies (including 844,246 participants and 5,737 MM cases), in compared the lower and higher caffeine intake daily, caffeinated coffee showed a the pooled relative risk (RR) of 0.81.

Risk of additional cup of coffee caffeine consumption, relative odd ratio of risk of melanoma deceased by 0.955
Importantly, the study found no correlated and linear dose dependent of decaffeinate coffee and risk melanoma regardless to volume of daily intake in teasing subjects.

Taking altogether, there is no doubt that caffeine coffee have a significant effect in reduced risk of malanoma in healthy and altered GSTM1 and GSTT1 expression subjects in linearly dose-dependent 

manner.

Arthritis Is Curable
You Can Eliminate Osteoarthritis
By addressing the Underlying Causes through Clinical Trials and Studies

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

FOOD HACK for Weight Loss
A Simple Cooking Technique That Cuts The Calories & Glycemic 
Impact In Rice, Pasta, And Potatoes In Half

Author biography
Kyle J. Norton, Master of Nutrients
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.

Sources
(1) The protective effect of coffee consumption on cutaneous melanoma risk and the role of GSTM1 and GSTT1 polymorphisms by Fortes C1, Mastroeni S, Boffetta P, Antonelli G, Pilla MA, Bottà G, Anzidei P, Venanzetti F.(PubMed)
(2) Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies by Micek A1, Godos J2, Lafranconi A3, Marranzano M2, Pajak A1(PubMed).